TrialNet is excited to announce the launch of our first Phase 1 clinical study to test a new plasmid therapy. The study will enroll 48 adults (age 18-45) diagnosed with type 1 diabetes (T1D) in the past 4 years.
At just 4 years old, Lilah Montgomery is fearless, outgoing, and a type 1 diabetes (T1D) research superhero!
During this difficult time for families around the world, staying at home is vitally important to controlling the spread of COVID-19. And, we’re continually amazed and thankful to see all the ways families are finding ways to make a difference.
At TrialNet, the health and safety of our participants and research teams is always our top priority.
Elliot, a 17-year-old from a small village outside Bristol, recently completed treatment in the Abatacept Prevention Study. He is the first person in the United Kingdom (UK) to do so.
Over 200 risk screening and study locations worldwide. Find A Location
